

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Yonsa (abiraterone acetate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Yonsa (abiraterone acetate)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Yonsa (abiraterone acetate) may be approved if the following criteria are met:

- I. Individual is diagnosed with metastatic castration-resistant* prostate cancer; **AND**
- II. Individual is using in combination with methylprednisolone.

*Castration-resistant refers to either surgical or medically induced methods. Medically induced methods include LHRH agonists [e.g. leuprolide, goserelin) or LHRH antagonists (e.g. degarelix).

Note: Metastatic castration-resistant prostate cancer occurs when cancer metastasizes beyond the prostate and disease progresses despite serum testosterone below castrate levels.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Yonsa [package insert]. Cranbury, NJ. Sun Pharma Global FZE; 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.